Filing Flows › AstraZeneca (AZN) › How it makes money
How AstraZeneca (AZN) makes money
AstraZeneca (AZN) made $30.7B of revenue in the second quarter 2026 (Q2 2026). Oncology brought in $14.1B (46%); BioPharmaceuticals brought in $11.2B (36%); Rare Disease brought in $4.9B (16%). Of every dollar of revenue, 83¢ was left as gross profit, 24¢ was left as operating profit, 18¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Oncology | $14.1B | 46.0% | — | — |
| BioPharmaceuticals | $11.2B | 36.4% | — | — |
| ↳ - Cardiovascular, Renal & Metabolism | $6.1B | 19.9% | — | — |
| ↳ - Respiratory & Immunology | $4.8B | 15.5% | — | — |
| ↳ - Infectious Disease | $312M | 1.0% | — | — |
| Rare Disease | $4.9B | 16.0% | — | — |
| Other Medicines | $486M | 1.6% | — | — |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $30.7B | 100.0% |
| Cost of revenue | $5.2B | 17.0% |
| Gross profit | $25.5B | 83.0% |
| Operating expenses | $18.1B | 58.9% |
| Operating profit | $7.4B | 24.2% |
| Income tax | $1.1B | 3.7% |
| Net earnings | $5.6B | 18.2% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $30.7B | +9% |
| Q1 2026 | $15.3B | +12% |
From AstraZeneca's 6-K filed Jul 27, 2026 (on EDGAR).
Questions
How does AstraZeneca make money?
AstraZeneca (AZN) made $30.7B of revenue in the second quarter 2026 (Q2 2026). Oncology brought in $14.1B (46%); BioPharmaceuticals brought in $11.2B (36%); Rare Disease brought in $4.9B (16%). Of every dollar of revenue, 83¢ was left as gross profit, 24¢ was left as operating profit, 18¢ was left as net earnings.
What is AstraZeneca's biggest business?
Oncology: $14.1B in the second quarter 2026, 46% of revenue.
What is AstraZeneca's profit margin?
Net earnings were $5.6B, 18.2% of revenue, in the second quarter 2026; the operating margin was 24.2%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.